HYREZTIQ Trademark

Trademark Overview

On Tuesday, August 9, 2016, a trademark application was filed for HYREZTIQ with the United States Patent and Trademark Office. The USPTO has given the HYREZTIQ trademark a serial number of 87132143. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 7, 2020. This trademark is owned by Pfizer Inc.. The HYREZTIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
hyreztiq

General Information

Serial Number87132143
Word MarkHYREZTIQ
Filing DateTuesday, August 9, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 7, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 6, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 12, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Tuesday, September 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 7, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, May 8, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 4, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 4, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 4, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, May 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, May 4, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, December 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 17, 2019EXTENSION 5 GRANTED
Thursday, December 12, 2019EXTENSION 5 FILED
Tuesday, December 17, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 12, 2019TEAS EXTENSION RECEIVED
Saturday, July 27, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 25, 2019EXTENSION 4 GRANTED
Thursday, July 25, 2019EXTENSION 4 FILED
Thursday, July 25, 2019TEAS EXTENSION RECEIVED
Saturday, January 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 3, 2019EXTENSION 3 GRANTED
Thursday, January 3, 2019EXTENSION 3 FILED
Thursday, January 3, 2019TEAS EXTENSION RECEIVED
Wednesday, July 18, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 16, 2018EXTENSION 2 GRANTED
Monday, July 16, 2018EXTENSION 2 FILED
Monday, July 16, 2018TEAS EXTENSION RECEIVED
Tuesday, January 9, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 5, 2018EXTENSION 1 GRANTED
Friday, January 5, 2018EXTENSION 1 FILED
Friday, January 5, 2018TEAS EXTENSION RECEIVED
Tuesday, August 1, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 6, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2017PUBLISHED FOR OPPOSITION
Wednesday, May 17, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 27, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 3, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 3, 2016NON-FINAL ACTION E-MAILED
Thursday, November 3, 2016NON-FINAL ACTION WRITTEN
Monday, October 31, 2016ASSIGNED TO EXAMINER
Friday, August 12, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, August 12, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

hyreztiq preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases